Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer

Several recently reported evidence-based phase 3 trials that focus on the role of cytotoxic chemotherapy have the potential to strongly influence the care of women with advanced epithelial ovarian cancer. Particular areas of interest include: (a) neoadjuvant chemotherapy; (b) chemotherapy of recurrent platinum-sensitive ovarian cancer; and (c) the relevance of paclitaxel scheduling in the primary chemotherapeutic management of the malignancy. This report will briefly discuss the results of these studies and the potential implications of the findings for routine care of patients in these clinical settings.

• Publication year

  2010

• Venue

  F1000 Medicine Reports

• Publication date

  2010-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3410/M2-29PMID 20948857PMCID 2948379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

  2010cited by this paper
• A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG).

  2009cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Ovarian cancer

  2009cited by this paper
• EORTC-GcG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA)

  2008cited by this paper
• Weekly paclitaxel in the adjuvant treatment of breast cancer.

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).

  2007cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002cited by this paper
• Prevention and Management of Antineoplastic-Induced Hypersensitivity Reactions

  2001cited by this paper
• Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.

  1999cited by this paper
• Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

  1998cited by this paper
• Molecular genetics for the clinician

  1993cited by this paper

• Neoadjuvant chemotherapy : Role in ovarian cancer

  2018cites this paper
• 6 Neoadjuvant Chemotherapy in Ovarian Cancer

  2017cites this paper
• Neoadjuvant Chemotherapy in Ovarian Cancer

  2012cites this paper